|
|
|
October 15, 2004
CoTherix, Inc. Announces Initial Public Offering of 5,000,000
Shares of Common Stock at $6.00 Per Share
CoTherix was founded as a specialty pharmaceutical
company dedicated to the treatment of severe pulmonary
disease. We invested in CoTherix after the company acquired
U.S. commercialization rights to inhaled iloprost, a prostacyclin
drug used to treat pulmonary hypertension. Our investment
in CoTherix enabled acquisition of the product from Schering
AG, subsequent NDA filing, and preparation for US launch.
Leveraging the events, CoTherix was able to go public
[NASDAQ: CTRX].
--------------------------------
CoTherix, Inc. (Nasdaq: CTRX) announced today the initial
public offering of 5,000,000 shares of common stock at
$6.00 per share. In addition, CoTherix has granted to
the underwriters a 30-day option to purchase up to 750,000
additional shares to cover over-allotments, if any. All
of the shares are being offered by CoTherix.
The shares are listed on The NASDAQ Stock Market under
the trading symbol "CTRX." The offering is being
managed by CIBC World Markets and Piper Jaffray &
Co.
Back to News
|
|
| |
